Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Sha Tin, Hong Kong Clinical Trials

A listing of Sha Tin, Hong Kong clinical trials actively recruiting patients volunteers.

RESULTS

Found (8) clinical trials

Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors RET Fusion-Positive Solid Tumors and Medullary Thyroid Cancer

This is an open-label, multi-center Phase 1/2 study in patients with advanced solid tumors, including RET fusion-positive solid tumors, MTC, and other tumors with RET activation. The trial will be conducted in 2 parts: phase 1 (dose escalation) and phase 2 (dose expansion). Patients with advanced cancer are eligible if ...

Phase

0.0 miles

Learn More »

A Study of TAS-120 in Patients With Advanced Solid Tumors

Phase 1 Dose Escalation Phase 1 Dose Escalation has been completed as of Dec 2017 Phase 1 Dose Expansion: Up to approximately 185 patients will be enrolled among the 8 groups as outlined below: Group 1- CCA (iCCA or eCCA) with FGFR2 gene fusions. Group 2- CCA (iCCA or eCCA) ...

Phase

0.0 miles

Learn More »

A Study of Brentuximab Vedotin + Adriamycin Vinblastine and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

The drug being tested in this study is called brentuximab vedotin. Brentuximab vedotin is being tested to treat pediatric participants who have advanced stage, newly diagnosed, classical CD30+ HL. This study will assess the safety, tolerability, and anti-tumor activity, as well as recommended dose of brentuximab vedotin in combination with ...

Phase

1.73 miles

Learn More »

Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC

The purpose of this study of INC280 and PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001 administered i.v. as a single agent or in combination with INC280 administered orally in adult patients with advanced hepatocellular carcinoma (HCC).

Phase

5.77 miles

Learn More »

A Study of IMU-131 Plus Standard of Care Chemotherapy in Patients With HER2/Neu Overexpressing Advanced Cancer of the Stomach

IMU-131 is a single peptide structure composed of 3 individual B-cell epitope peptide sequences selected from HER2/neu structure. Polyclonal antibodies against IMU-131 peptides bind three separate regions of the HER2 receptor and also to the dimerization loop of the HER2 receptor, preventing dimerization, which in turn inhibits intracellular signaling. This ...

Phase

5.77 miles

Learn More »

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

The purpose of this study of MCS110 with PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with PDR001 in adult patients with solid tumors.

Phase

5.77 miles

Learn More »

Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies

The purpose phase I of this trial is to characterize safety and tolerability and determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of MAK683. The purpose of the phase II of this trial will be to evaluate the anti-tumor activity of MAK683.

Phase

5.77 miles

Learn More »

Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

In the first part of the study (Part 1, dose-escalation), Sym015 will be evaluated for safety and tolerability. Additionally, the recommended phase 2 dose (RP2D) will be determined. Sym015 will be given at different dose levels on an every second week (Q2W) dosing schedule. Each patient will be given one ...

Phase

5.77 miles

Learn More »